Clinical Trials Sponsored by Theravant Corporation

Total 6523 results

Theravant Corporation

Completed

Effects of Acleara Needle Insert on Acne

Acne Vulgaris

United States
Theravance Biopharma

Terminated

Efficacy and Safety of TD-1473 in Crohn's Disease (DIONE)

Crohn's Disease

United States, Bulgaria, France, Georgia, Germany, Greece, Hungary, Israel, Korea, Republic of, Poland, Portugal, Romania, Serbia, South Africa, Spain, Ukraine, Australia, Austria, Croatia, New Zealand, Russian Federation, United...
Theravance Biopharma

Completed

TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH)

Parkinson Disease | Orthostatic Hypotension | Neurogenic Orthostatic Hypotension | Hypotension, Orthostatic | Pure Autonomic Failure | Multiple System Atrophy (MSA) With Orthostatic Hypotension | Pure Autonomic Failure With Orthostatic Hypotension | Parkinson Disease With Orthostatic Hypotension

United States
Theravance Biopharma

Completed

A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

ADHD | Attention-Deficit/Hyperactivity Disorder

United States
Theravance Biopharma

Completed

Comparison of Viral Particle Dispersion Following Administration of an MDI or Nebulizer in Subjects With COVID-19

COVID-19

United States
Theravance Biopharma

Completed

First in Human SAD and MAD Study of Inhaled TD-0903, a Potential Treatment for ALI Associated With COVID-19

Acute Lung Injury (ALI) Associated With COVID-19 | Inflammatory Lung Conditions Associated With COVID-19

United Kingdom
Theravance Biopharma

Completed

Single Dose Bioavailability and Ethnobridging PK Study in Healthy Subjects

Bowel Diseases, Inflammatory | Intestinal Disorder

United States
Theravance Biopharma

Completed

A Fixed-Sequence, Two-Period, Open-Label Drug-Drug Interaction Study to Assess the Effect of an Inhibitor of Cytochrome P450 Isoenzyme 3A4 and Permeability Glycoprotein 1 on the Pharmacokinetics of TD-1211

Healthy

United States
Theravance Biopharma

Completed

Multiple Ascending Dose Study of TD-0714 in Healthy and Elderly Subjects

Healthy Adults, Elderly Subjects

United States
Theravance Biopharma

Completed

TD-6450 MAD Study in HCV Infected Subjects

Hepatitis C | HCV

United States
Theravance Biopharma

Completed

TD-1473 Absorption, Distribution, Metabolism and Excretion (ADME) Study in Healthy Male Subjects

Bowel Diseases, Inflammatory | Intestinal Disorders

United States
Theravance Biopharma

Completed

Multiple Dose Ethnobridging PK Study in Healthy Subjects

Inflammatory Bowel Diseases | IBD

United States
Theravance Biopharma

Completed

TD-1211 Single-Dose Study in Elderly and Young Healthy Subjects

Constipation

United States
Theravance Biopharma

Completed

Safety, Pharmacokinetics and Pharmacodynamics of Velusetrag in Healthy Elderly Subjects

Alzheimer's Disease

United States
Theravance Biopharma

Terminated

Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure (REDWOOD)

Parkinson's Disease (PD) | MSA | Symptomatic Neurogenic Orthostatic Hypotension | Pure Autonomic Failure (PAF)

United States, Spain, United Kingdom, Canada, France, Estonia, Australia, Israel, Denmark, Italy, Poland, New Zealand, Germany, Ukraine, Austria, Bulgaria, Portugal, Hungary, Russian Federation
Theravance Biopharma

Terminated

TD-1473 Long-Term Safety (LTS) Ulcerative Colitis (UC) Study

Ulcerative Colitis (UC)

United States, Australia, Bulgaria, Canada, France, Georgia, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Poland, Portugal, Romania, Serbia, Slovakia, South Africa, Spain, Taiwan, Ukraine
Theravance Biopharma

Completed

TD-0903 for ALI Associated With COVID-19

Acute Lung Injury (ALI) Associated With COVID-19 | Lung Inflammation Associated With COVID-19

Moldova, Republic of, United Kingdom, United States, Brazil, Finland, Romania, Ukraine
Theravance Biopharma

Terminated

TD-1058 First-In-Human Study in Healthy Subjects and Subjects With Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis (IPF)

United Kingdom
Theravance Biopharma

Completed

TD-0903 Pharmacokinetics Study in Healthy Participants With Supplemental Oxygenation

Acute Lung Injury (ALI) Due to Coronavirus Disease-2019 (COVID-19)

United States
Theravance Biopharma

Completed

Effect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of TD-9855

Symptomatic Neurogenic Orthostatic Hypertension | nOH

United States
Theravance Biopharma

Completed

A Study of TD-1211 in Subjects With Opioid-Induced Constipation (OIC)

Opioid Induced Constipation

United States
Theravance Biopharma

Completed

Thorough QT Study to Evaluate Ampreloxetine in Healthy Subjects

Symptomatic Neurogenic Orthostatic Hypertension | nOH

United States
Theravance Biopharma

Completed

Multiple Ascending Dose Study of TD-1439 in Healthy Adult and Elderly Subjects

Healthy Adults, Elderly Subjects

United States
Theravance Biopharma

Completed

Single Ascending Dose Study of TD-1439 in Healthy Subjects

Healthy Subjects

United States
Theravance Biopharma

Completed

SAD and MAD Study to Evaluate Safety, Tolerability, and Pharmacokinetics (PK) of TD-1473 in Healthy Subjects

Healthy

United States
Theravance Biopharma

Completed

TD-1607 SAD Study in Healthy Subjects

Serious Infections Due to Known or Suspected Gram-positive Pathogens

United States
Theravance Biopharma

Completed

TD-9855 Mass Balance Study

Fibromyalgia | ADHD

United States
Theravance Biopharma

Completed

Drug-Drug Interaction (DDI) Study for TD-9855

Drug Drug Interaction (DDI)

United States
Theravance Biopharma

Completed

Food-effect, Drug-Drug Interaction (DDI), and Formulation Bridging Study

Inflammatory Bowel Disease

United States
Theravance Biopharma

Completed

TD-6450 SAD and MAD in Healthy Subjects

Hepatitis C

United States
TheraVasc Inc.

Completed

Phase IIa: Safety, PK, & Tolerability of Sodium Nitrite in Patients With Peripheral Arterial Disease-SONIC

Peripheral Arterial Disease

United States
Theravance Biopharma

Terminated

A Phase 1, Multiple Intravenous Dose Study to Examine Safety, Tolerability, and PK of Intravenous TD-8954, a 5-HT4 Receptor Agonist, in Healthy Subjects

Gastrointestinal Motility Disorder

United States
Theravance Biopharma

Completed

Evaluate the Safety and Efficacy of a 5-HT4 Agonist in Chronic Constipation (ACCORD Trial)

Chronic Constipation

United States
Theravance Biopharma

Recruiting

Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy (CYPRESS)

MSA - Multiple System Atrophy | Symptomatic Neurogenic Orthostatic Hypotension

United States, Spain, United Kingdom, Hungary, Italy, Argentina, Austria, Poland, Germany, Portugal, Belgium, Brazil, Denmark, Estonia, Canada, France, Chile
Theravance Biopharma

Terminated

Phase 3 Open-Label Extension Study of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure (OAK)

Symptomatic Neurogenic Orthostatic Hypotension

United States, Spain, Portugal, United Kingdom, France, Denmark, Ukraine, Israel, Estonia, Poland, Italy, Russian Federation, Australia, Austria, Bulgaria, Canada, Germany, New Zealand
Theravance Biopharma

Terminated

Efficacy & Safety of TD-1473 in Ulcerative Colitis (RHEA)

Ulcerative Colitis (UC)

United States, Australia, Bulgaria, Canada, France, Georgia, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Poland, Portugal, Romania, Serbia, Slovakia, South Africa, Spain, Taiwan, Ukraine
Theravance Biopharma

Completed

Clinical Effect of Ampreloxetine (TD-9855) for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure (SEQUOIA)

Symptomatic Neurogenic Orthostatic Hypotension

United States, Spain, Israel, Hungary, Portugal, Australia, Canada, Germany, Russian Federation, Estonia, France, Italy, United Kingdom, Denmark, Poland, New Zealand, Austria, Bulgaria, Ukraine
Theravance Biopharma

Completed

Effect of Inhaled TD-8236 on Allergen-induced Asthmatic Response

Asthma

United Kingdom
Theravance Biopharma

Completed

Phase 2 Study of TD-9855 to Treat Fibromyalgia

Fibromyalgia

United States
Theravance Biopharma

Completed

Single Ascending Dose Study of TD-0714 in Healthy Subjects

Healthy

United States
Theravance Biopharma

Completed

TD-1473 for Active Ulcerative Colitis (UC)

Ulcerative Colitis, Active Severe | Ulcerative Colitis, Active Moderate

United States, Georgia, Moldova, Republic of, Romania
Theravance Biopharma

Completed

Single and Multiple Ascending Dose Study of TD-8236 by Inhalation

Asthma

United Kingdom
Theravance Biopharma

Completed

A Study to Assess the Safety, Tolerability and Clinical Activity of TD-1211 in Patients With Opioid-Induced Constipation

Opioid-induced Constipation (OIC)

United States
Theravance Biopharma

Completed

A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of TD-1211 in Subjects With Opioid-Induced Constipation

Opioid Induced Constipation

United States
Theravance Biopharma

Completed

A Multiple Dose Study of TD-1211 in Healthy Volunteers and Patients With Opioid-Induced Constipation

Healthy | Opioid-induced Constipation

United States
Theravance Biopharma

Completed

TD-1211 IV/Oral Mass Balance Study

OIC

United States
Theravance Biopharma

Completed

TD-1792 in Gram-positive Complicated Skin and Skin Structure Infection

Staphylococcal Skin Infection

United States
Theravance Biopharma

Completed

TD-1607 MAD Study in Healthy Subjects

Infections | Bacterial Infections

United States
Theravance Biopharma

Completed

Single and Multiple Ascending Dose, First-in- Human Study in Healthy Subjects

Healthy

United States
Theravance Biopharma

Completed

TD-3504 SAD in Healthy Subjects and Subjects With Ulcerative Colitis (UC)

Active Mild Ulcerative Colitis, Active Moderate Ulcerative Colitis, Healthy Subjects

United States

Clinical Trials Sponsored by Theravant Corporation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Guatemala

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations